Beijing Shuoxing Biomedical Technology
VHH antibody drug discovery and engineering platform.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY20.0m | Series A | |
| Total Funding | 000k | ||
Beijing Shuoxing Biomedical Technology, also known as Starmab, is a biopharmaceutical company founded in 2019 by Dr. Liang Yanbin. The company operates from research and development centers in both Beijing, China, and California, USA. Starmab specializes in the discovery and development of innovative antibody drugs, focusing on therapeutic areas such as oncology, inflammatory diseases, and ophthalmology.
The company's core technology is its VHH antibody discovery and engineering optimization platform. This platform is designed to efficiently screen for and optimize VHH antibodies, which are smaller and more stable than conventional antibodies, to generate drug candidates with high affinity and biological activity. Starmab has developed a pipeline of products, including its nano-multispecific antibody drug SM3321, which targets tumors. In May 2022, SM3321 received clinical trial approval from the U.S. FDA, and it is also undergoing clinical trials in China.
The business model centers on the research, development, and eventual commercialization of these proprietary biologic drugs globally. Starmab has successfully raised significant capital to fund its research and clinical trials. After its establishment in 2019, it secured a nearly 100 million RMB Series A round in February 2022, led by CICC Capital, to advance two drug candidates into CMC production and clinical filings in the US and China. This was followed by a Series A+ round of several tens of millions of RMB in early 2024 to further advance its nano-multispecific antibody drug development.
Keywords: VHH antibody, nanobody, biopharmaceutical, oncology, drug discovery, antibody engineering, multi-specific antibodies, clinical trials, inflammatory diseases, ophthalmology, SM3321, biologics, protein engineering, cancer therapy, immunotherapy